Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Med Inform Decis Mak ; 20(1): 199, 2020 08 24.
Article in English | MEDLINE | ID: mdl-32838772

ABSTRACT

BACKGROUND: Family-centered care is a valued approach to improving child and family outcomes in early intervention (EI), yet there is need to implement interventions that support information exchange for shared decision-making when planning and monitoring EI care. This study aims at estimating the feasibility, acceptability, and value of implementing the Young Children's Participation and Environment Measure (YC-PEM), a valid electronic patient-reported outcome (e-PRO) that is designed to support family engagement when planning care and monitoring outcomes of care. METHODS: Data were gathered from caregivers (N = 139) that were enrolled in a Phase 1 trial of the YC-PEM e-PRO as implemented within 1 month of their child's next EI evaluation of progress. YC-PEM e-PRO feasibility was estimated according to enrollment and completion rates, and mean completion time. Chi-square tests were used to examine parent perceptions of YC-PEM e-PRO acceptability by caregiver education and family income. Caregiver feedback via open-ended responses were content coded to inform intervention and protocol optimizations. YC-PEM e-PRO value was estimated via composite and item-level scores to capture the extent of participation difficulty in home and community activities, and common areas of need regarding caregivers desired change in their child's participation. RESULTS: Feasibility of implementing the YC-PEM e-PRO in routine EI care was mixed, as evidenced by low enrollment rates (21.0-29.2%), a high completion rate (85.3%), and limited missing data (80.6% of completed cases contained no missing data). More than half of the participants reported that the completion of the YC-PEM e-PRO was at least somewhat helpful, regardless of family income or caregiver education, providing support for its acceptability. As for its value, the YC-PEM e-PRO results were viewed by 64% of caregivers, whose desire for change most often pertained to the child's participation in non-discretionary activities at home and structured activities in the community. CONCLUSIONS: Results may support the implementation of YC-PEM e-PRO as a feasible, acceptable, and valued option for engaging families in planning the child's EI care. Results also inform select intervention and protocol optimizations prior to undertaking a multi-site pragmatic trial of its effectiveness on family engagement and shared decision-making within an EI clinical workflow. TRIAL REGISTRATION: Trial number: NCT03904797 . Trial registered at Clinicaltrials.gov . Registered 22 March 2019. Retrospectively registered.


Subject(s)
Caregivers , Family , Patient Reported Outcome Measures , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Male , Parents , Surveys and Questionnaires , Young Adult
2.
Rev Sci Tech ; 25(2): 637-53, 2006 Aug.
Article in English | MEDLINE | ID: mdl-17094703

ABSTRACT

The authors present an overview of the presence of residues from veterinary medicinal products, growth-promoting agents and performance enhancers in food-producing animals, as a result of administering these substances--legally or illegally--on farms. The current situation in the European Union (EU) is represented by an analysis of the 2004 results from the national residue monitoring plans of EU Member States. Aspects of ante-mortem and postmortem inspection are also considered, as well as the practical challenges facing veterinary inspectors attempting to uncover illegal uses and prevent public health risks. Substances which are considered illegal because their risks have not yet been assessed, such as those employed in minority species or for minor uses, are also discussed.


Subject(s)
Animal Welfare , Drug Residues/analysis , Food Contamination/analysis , Legislation, Food , Meat/standards , Animals , Consumer Product Safety , Drug Residues/adverse effects , European Union , Food Contamination/prevention & control , Humans , Veterinary Medicine/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...